SMO and skin basal cell carcinoma: Small molecule inhibitors such as vismodegib and sonidegib, which target SMO (Smoothened) in the Shh pathway, have been FDA-approved for treatment of advanced BCC [8]; however, they are limited by their severe side effects and failure of complete patient response [9].